Status unknownNCT05234762Updated Mar 2, 2023

Efficacy, Safety, and Pharmacokinetics of ES-481 in Adult Patients With Essential Tremors

A Phase 2 interventional study of ES-481 and Placebo in Tremor, Essential, sponsored by ES Therapeutics Australia Pty Ltd. Status unknown at 1 site in Canada. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-03-02.

Sponsored by ES Therapeutics Australia Pty Ltd · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Recruiting — may be out of date.

Phase: Phase 2
Study type: Interventional
Enrollment: 24
Allocation: Randomized
Ages: 18 Years to 75 Years
Sex: All

Study summary

This Pilot Phase 2A study will investigate the safety, tolerability, and pharmacokinetics (PK) of ES-481 in adult patients with essential tremor.

Conditions studied

Tremor, Essential

Browse trials for

In context

Tremor

257 studies on the registry are indexed under Tremor; 59 are open to participants now.

This study's planned enrollment of 24 is close to the median of 25 across 184 interventional studies indexed under Tremor.

Browse Tremor studies →

Lead sponsor

ES Therapeutics Australia Pty Ltd is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 75 Years
Sexes eligible: All
Accepts healthy volunteers: No

Inclusion criteria

Written and Signed Informed Consent
Age 18 to 75 years old
The Subject must have Essential Tremor (ET). ET is defined as at least 1 upper extremity with a tremor score ≥ 1.5 in forward posture, wing beating posture, or finger-to-nose movement using the Performance subscale of The Essential Tremor Rating Assessment Scale (as per by the Tremor Investigation Group criteria).
Subject has a diagnosis of essential tremor, as defined by all the following criteria: (a) isolated tremor syndrome consisting of bilateral upper limb action; (b) at least three years duration; (c) with or without tremor in other location (e.g., head, voice, or lower limb).
The Subject must be on stable dose of anti-tremor medication in the four (4) weeks prior to screening and must willing to maintain their current dose for the duration of the study.
The Subject had no prior surgery for tremor.
The Subject had no botulinum injection for at least six (6) months prior to -screening.
The Subject does not have a significant imbalance or risk fall.
The Subject has not previously taken perampanel.

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded from 7-day screening period or study enrollment into the Treatment Period 1, if they meet any of the following criteria:

Unwilling or inability to follow the procedures specified by the protocol
Pregnancy or breast feeding
Women of child-bearing potential and men who are unable or unwilling to take adequate contraceptive precautions, including one of the following:
- Hormonal contraception (birth control pills, injected hormones, or vaginal ring)
- Intrauterine device
- Barrier methods (condom or diaphragm) combined with spermicide
- Surgical sterilization (hysterectomy, tubal ligation, or vasectomy)
History (within the last year) of illicit drug use or alcohol dependence or a positive screen for alcohol on the Day 1 visit, or a positive screen for drugs of abuse at Screening or at the Day 1 visit
Subject is unwilling or unable to refrain from alcohol 24 hours before and during clinical trial visits, or regular use of alcohol that would preclude abstinence from alcohol for time periods around visits.
Subject has a history of substance use disorder consistent with Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria, in the opinion of the Principal Investigator,
Concomitant treatment with more than three drugs to treat essential tremors
Subject has had recent exposure (14 days prior to Day 1) to tremorgenic drugs.
Subject has had direct or indirect injury or trauma to the nervous system within 3 months before the onset of tremor.
Subject has a history or clinical evidence of other medical, neurological, or psychiatric conditions that may explain or cause tremors, including but not limited to Parkinson's disease, Huntington's disease, cerebellar disease (including spinocerebellar ataxias, primary dystonia, Fragile X Tremor/Ataxia syndrome or Family history of Fragile X syndrome, traumatic brain injury, psychogenic tremor, alcohol or benzodiazepines abuse or withdrawal, multiple sclerosis, polyneuropathy, and endocrine states such as hyperthyroidism or unstable treatment of hypothyroidism or medication, food, or supplement induced movement disorder (e.g., tremor related to beta agonists or caffeine), or other medical, neurological or psychiatric condition that may explain or cause tremors.
Subject has had a previous procedure for the treatment of ET, deep brain stimulation, brain lesioning, or magnetic resonance (MR)-guided procedure, e.g., MR-guided focused ultrasound.
Subject has historical or clinical evidence of tremor with psychogenic origin (including but not limited to eating disorders, major depression, etc.).
Subject has history of suicidal behavior within 2 years or is currently at risk for suicide in the opinion of the investigator.
Subject has any neurological abnormality other than ET upon neurological exam, including dystonia, ataxia, or any other neurodegenerative disease, including multiple sclerosis.
Subject has alkaline phosphatase, aspartate aminotransferase (AST), and/or alanine aminotransferase (ALT) level >3.0 x upper limit of normal (ULN) at Screening and/or at Pre-dose.
Subject has serum creatinine >120 μmol/L and/or creatinine clearance \<60 mL/min (according to Cockcroft-Gault formula) at Screening.
Subject has a history of Long QT syndrome and/or QTcF (Fridericia's correction) interval >450 msec (males) or >470 msec (females) per 12-lead ECG done at Screening.
Subject has a diagnosis of epilepsy or any history of seizure as an adult; head trauma, stroke, transient ischemic attack within 1 year prior to Screening; unexplained loss of consciousness within 1 year prior to Screening; or any lifetime history of asymptomatic or symptomatic orthostatic hypotension (e.g., postural syncope)
Subject has a history of unstable angina, myocardial infarction, chronic heart failure (New York Heart Association Class 3 or 4), or clinically significant conduction abnormalities (e.g., unstable atrial fibrillation) within 1 year prior to screening.
Subject has any major psychiatric disorder that is uncontrolled (for the past 90 days) that, per the Investigator's judgment, can interfere with any of the study procedures.
Subject should not have received treatment with another investigational drug within 30 days or 5 half-lives (whichever is longer), prior to the screening visit.
Subject should not have received a vaccine within 60 days prior to study drug administration, except for vaccines related to Covid-19.
Subject should not have donated or lost more than 450mL of blood or received a transfusion of any blood or blood products within 90 days prior to screening, or donated plasma within 7 days prior to admission.
Subject has a known allergy to ES-481 or its excipients.

Study design

Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Crossover assignment
Masking: Double (Participant, Investigator)
Enrollment: 24 participants (estimated)

Study arms

Experimental
ES-481
Week 1 - 25 mg qd (2 x 25 mg capsule in the mornings Days 1 to 7 in Treatment Period 1 and Days 44 to 50 in Treatment Period 2) Week 2 - 50 mg bid (2 x 25 mg capsule in the mornings and 2 x 25 mg capsules in the evening on Days 8 to 14 in Treatment Period 1 and Days 51 to 57 in Treatment Period 2) Week 3 - 75 mg bid (2 x 25 mg capsule in the mornings and 2 x 25 mg capsules in the evening on Days 15 to 21 in Treatment Period 1 and Days 58 to 64 in Treatment Period 2) Week 4 - 75 mg bid (2 x 25 mg capsule in the mornings and 2 x 25 mg capsules in the evening on Days 22 to 28 in Treatment Period 1 and Days 65 to 71 in Treatment Period 2)
Drug: ES-481
Placebo comparator
Placebo
Placebo will be dosed at the same quantity and frequency as ES-481 just as Placebo HPMC capsules
Other: Placebo

Interventions

DrugES-481
Dose escalation during two Treatment Periods
OtherPlacebo
Placebo dosed at same dosing as ES-481

What researchers measure

Primary outcomes

Performance Subscale of The Essential Tremor Rating Assessment Scale (TETRAS-P)
To evaluate postural and kinetic tremor of body parts affected by ET, with emphasis on upper extremity tremor. Items are scored from 0 to 4, with 4 representing the highest severity.
Time frame: Collected during 6 days throughout the study, scores to be combined.
Number of participants with abnormal laboratory test results
Collection of: Total protein
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Sodium
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Potassium
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Calcium
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Chloride
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Albumin
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Glucose
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Blood urea nitrogen (BUN)
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Creatinine
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Carbon dioxide (CO2)
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Uric acid
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Total bilirubin
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Alkaline phosphatase (AP)
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: AST
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: ALT
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Gamma-glutamyl transpeptidase (GGT)
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Lactate dehydrogenase (LDH)
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Creatine phosphokinase (CPK)
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Hemoglobin
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Hematocrit
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Red blood cell (RBC) count
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: White blood cell (WBC) count with differential
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Mean corpuscular volume (MCV)
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Mean corpuscular hemoglobin (MCH)
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Mean corpuscular hemoglobin (MCHC)
Time frame: Through study completion, an average of 78 days.
Number of participants with abnormal laboratory test results
Collection of: Absolute platelet count
Time frame: Through study completion, an average of 78 days.
Safety assessments through collection of serious adverse events
Collection of Serious Adverse Events
Time frame: Through study completion, an average of 78 days.
Safety assessments through collection of adverse events
Collection of Adverse Events
Time frame: Through study completion, an average of 78 days.
Safety assessments through collection of treatment emergent adverse events
Collection of Treatment Emergent Adverse Events
Time frame: Through study completion, an average of 78 days.
Plama samples for PK
Will be collected to assess the plasma concentration of ES-481 during the 28-day treatment periods from both ES-481 and Placebo subjects to estimate the PK of ES-481 After the study blind is broken, only the samples from subjects who took ES-481 will be analyzed.
Time frame: Will be collected on Days 1, 22, 29, 44, 65, and 72

Secondary outcomes

Activity of Daily Living
Subjects will complete a 12-item (0-4 ratings) Activity of Daily Living questionnaire.
Time frame: Will be completed on Days 1 (baseline and prior to administration of study medication on Day 1 in Treatment Period 1), and Days 22, 29, 44 (baseline and prior to administration of study medication on Day 44 in Treatment Period 2), 65, and 72
Subject Global Impression of Change Scale (SGIC)
Subjects will rate overall change with the Subject Global Impression of Change Scale in which change was rated between minus 3 and plus 3, with 1 connoting mild change, 2 moderate change, and 3 marked changes, with minus indicating improvement and plus worsening
Time frame: Will be completed on Days 1 (baseline and prior to administration of study medication on Day 1 in Treatment Period 1), and Days 22, 29, 44 (baseline and prior to administration of study medication on Day 44 in Treatment Period 2), 65, and 72

Study locations

1 of 1 sites recruiting

Clinique Neuro-Levis
Levis, Quebec, Canada
- Manon Bouchard · Contact
Recruiting

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Mar 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT05234762
Lead sponsor: ES Therapeutics Australia Pty Ltd
Responsible party: Sponsor
First posted: Feb 10, 2022
Start date: Nov 21, 2021
Primary completion: Dec 31, 2023 (estimated)
Completion: Dec 31, 2023 (estimated)
Last update: Mar 2, 2023

Study contacts

Robert Niecestro, PhD

Contact

rniecestro@estherapeutics.com

+1-917-733-5311

Oversight

FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Tremor→

Other studies from this sponsor

ES Therapeutics Australia Pty Ltd

Start the discussion